Asian Pacific Journal of Cancer Prevention · 2015 · 32 citations · 25 references
MedicineGeneticsMolecular GeneticsMedical GeneticsPediatric GeneticsPharmacogeneticsDrug Transporter GeneticsGenetic Risk AssessmentPediatric Cancer GeneticsPediatric LeukemiasPharmacogenomics In ChildrenPharmacogenomics In Pediatric OncologyMedian AgeMolecular Prognostic MarkersMolecular Risk MarkersMulti-drug ResistanceP-glycoprotein TransportRestriction Fragment Length Polymorphism AnalysisTransporter Gene PolymorphismsTransporter Genetic Polymorphisms
BACKGROUND: MDR1, one of the most important drug-transporter genes, encodes P- glycoprotein (P-gp)-a transporter involved in protecting against xenobiotics and multi-drug resistance. The significance of the genetic background in childhood acute lymphoblastic leukemia (ALL) is not well understood. MATERIALS AND METHODS: To evaluate whether C3435T and C1236T MDR1 polymorphisms are associated with the occurrence and outcome of ALL, 208 children with ALL (median age 5.0 yr) and 101 healthy Thai children were studied by polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) assay. RESULTS: C3435T and C1236T MDR1 polymorphism are significantly associated with the high-risk group (OR=2.6, 95%CI=1.164-5.808; P=0.028 and OR=2.231, 95%CI=1.068-4.659; p=0.047, respectively), indicating that both may be candidates for molecular markers in the high-risk group of ALL.
25
Sven Hoffmeyer, Oliver Burk, Oliver von Richter et al. · Proceedings of the National Academy of Sciences · 2000 · 2.4K citations
Monika Hitzl, Siegfried Drescher, Heiko van der Kuip et al. · Pharmacogenetics · 2001 · 374 citations